BioAge Labs (BIOA) Liabilities and Shareholders Equity (2023 - 2026)

BioAge Labs has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $396.9 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 23.21% year-over-year to $396.9 million; the TTM figure through Jun 2026 stood at $1.4 billion (up 2.42% YoY), while the FY2025 annual figure was $294.9 million, down 17.68% from the prior year.
• Liabilities and Shareholders Equity came in at $396.9 million for Q2 2026 at BioAge Labs, roughly flat from $397.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $397.7 million in Q1 2026 to a low of $25.9 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 4 years is $309.1 million, with a median of $337.4 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity surged 1281.86% in 2024 and decreased 17.68% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $25.9 million in 2023, then surged by 1281.86% to $358.2 million in 2024, then slipped by 17.68% to $294.9 million in 2025, then jumped by 34.6% to $396.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $396.9 million in Q2 2026, $397.7 million in Q1 2026, and $294.9 million in Q4 2025.